Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 4 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Vitamin D Deficiency 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Neoplasms 1Multiple Sclerosis, Relapsing-Remitting 1Multiple Endocrine Neoplasia Type 1 1Inflammation 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Vincristine 20Cytarabine 19Methotrexate 18Dexamethasone 17Cyclophosphamide 17Mercaptopurine 16Daunorubicin 12Asparaginase 12Doxorubicin 10Prednisolone 9Granulocyte Colony-Stimulating Factor 8Idarubicin 7Etoposide 7Thioguanine 6Teniposide 6Rituximab 6Prednisone 6Vindesine 5Ifosfamide 5Stem Cell Transplantation 4fludarabine 3Mitoxantrone 3Hydrocortisone 3pegaspargase 2Ketamine 2Inotuzumab Ozogamicin 2Imatinib Mesylate 2Cladribine 2Cholecalciferol 2pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Vitamin D × Clear all
NCT05340985 2022-04-22

Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis

Tehran University of Medical Sciences

Phase 4 Unknown
54 enrolled
LymphoidOther hematologic neoplasm

Multiple Sclerosis, Relapsing-Remitting, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡